← Browse by Condition
Medical Condition

neoadjuvant therapy

Total Trials
9
Recruiting Now
9
Trial Phases
Phase 3, Phase 2, Phase 4

ClinicalMetric tracks all active clinical trials for neoadjuvant therapy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — neoadjuvant therapy Clinical Trials

How many clinical trials are currently recruiting for neoadjuvant therapy?
ClinicalMetric currently tracks 9 actively recruiting clinical trials for neoadjuvant therapy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neoadjuvant therapy?
neoadjuvant therapy research spans Phase 2 (6 trials), Phase 3 (2 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neoadjuvant therapy clinical trial?
Eligibility criteria for neoadjuvant therapy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
6
Phase 3
2
Phase 4
1
Top Sponsors
Beijing Tongren Hospital 1 trial
Seventh Medical Center of PLA General Hospital 1 trial
The First Affiliated Hospital with Nanjing Medical University 1 trial
Wen-Ming Cao 1 trial
Second Affiliated Hospital, Zhejiang University, School of Medicine 1 trial

Recruiting Clinical Trials

NCT06102395 Phase 3
Recruiting
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Enrollment
272 pts
Location
China
Sponsor
Beijing Tongren Hospital
View Trial →
NCT07458529 Phase 2
Recruiting
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
Enrollment
50 pts
Location
China
Sponsor
Seventh Medical Center of PLA ...
View Trial →
NCT07847710 Phase 2
Recruiting
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial
Enrollment
81 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT07695259 Phase 4
Recruiting
Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer
Enrollment
45 pts
Location
China
Sponsor
Wen-Ming Cao
View Trial →
NCT07505186 Phase 2
Recruiting
Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Enrollment
45 pts
Location
China
Sponsor
Second Affiliated Hospital, Zh...
View Trial →
NCT06758830 Phase 2, Phase 3
Recruiting
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
Enrollment
400 pts
Location
Lithuania
Sponsor
National Cancer Center Affilia...
View Trial →
NCT07372079 Phase 2
Recruiting
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
Enrollment
40 pts
Location
China
Sponsor
Tianjin Medical University Can...
View Trial →
NCT07388771
Recruiting
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer(NSCLC)
Enrollment
500 pts
Location
China
Sponsor
Qian Chu
View Trial →
NCT07492342 Phase 2
Recruiting
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
Enrollment
30 pts
Location
China
Sponsor
Jianxing He
View Trial →

Related Conditions

head and neck squamous cell carcinoma (1) pembrolizumab (1) rectal cancer adenocarcinoma (1) immunotherapy (1) probio m9 (1) tislelizumab (1) randomized (1) intrahepatic cholangiocarcinoma icc (1) elderly females (1) her2 breast cancer (1) esophageal squamous cell carcinoma (1) rectal cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology